Table 1.
Group I and II baseline characteristics and CAD risk factors, pharmacotherapy
| mean (+/-) | |||
|---|---|---|---|
| group I | group II | p | |
| Male:female ratio (%) | 28:17 (62.2%) | 14:3 (82.3%) | 0.13 |
| age [years old] | 58.5 (1.95) | 61.4 (1.92) | 0.18 |
| waist diameter[cm] | 98.71 (1.40) | 104.88 (2.43) | 0.04 |
| BMI [kg/m2] | 28.95 (0.46) | 29.66 (1.01) | 0.53 |
| Positive family history for CAD | 24 (54.5%) | 8(46.6%) | 0.60 |
| hipercholesterolemia during statin or fibrate treatment or LDL >3 mmol/l | 44 (97.78%) | 16 (94.12%) | 0.48 |
| Diabetes | 7 (15.56%) | 6 (35.29%) | 0.10 |
| smoking | 25 (55.56%) | 11 (64.71%) | 0.51 |
| hypertension | 39 (86.67%) | 16 (94.12%) | 0.66 |
| Overweight or obesity | 42 (93.33%) | 15 (88.24%) | 0.61 |
| Total cholesterol [mmol/l] | 5.02 (0.18) | 4.55 (0.20) | 0.14 |
| LDL [mmol/l] | 2.92 (0.15) | 2.69 (0.17) | 0.40 |
| HDL [mmol/l] | 1.23 (0.05) | 1.21 (0.07) | 0.77 |
| TG [mmol/l] | 1.63 (0.12) | 1.37 (0.23) | 0.30 |
| CCS: | |||
| CCS I | 5 (11.11%) | 2 (11.76%) | 0.94 |
| CCS II | 24 (53.33%) | 7 (41.18%) | 0.39 |
| CCS III | 4 (8.89%) | 8 (47.06%) | < 0,001 |
| Non-specific symptoms | 12 (26.67%) | 0 (%) | 0.02 |
| pharmacotherapy: | |||
| acetylosalicylic acid | 41 (91.1%) | 16 (94.1%) | 0.70 |
| ACEI | 38 (84.4%) | 15 (88.2%) | 0.71 |
| statin | 35 (77.8%) | 14 (82.4%) | 0.69 |
| beta-blocker | 30 (66.7%) | 11 (64.7%) | 0.88 |
| nitrate | 20 (44.4%) | 12 (70.6%) | 0.07 |
| Ca-blocker | 11 (24.4%) | 7 (41.2%) | 0.20 |
| diuretic | 12 (26.7%) | 3 (17.6%) | 0.46 |
| fibrate | 3 (6.7%) | 1 (5.9%) | 0.91 |
| ARB | 2 (4.4%) | 0 (0.0%) | 0.38 |
BMI body mass index; CAD coronary artery disease; CCS Canadian Cardiovascular Society scale; ACEI angiotensin convering enzyme inhibitor; ARB angiotensin receptor blocker